The latest World Health Organization report indicates that cancer has become the No. 1 killer of human health. According to statistics, there will be an annual increase of cancer patients of 22 million in the next 20 years worldwide, and the cancer-related deaths will rise from 8.2 million to 13 million each year in the same period.
The treatments currently in use are surgical operations, radiotherapy, chemotherapy, biotherapy and Traditional Chinese Medicine (TCM) therapy.
Photodynamic therapy (PDT) is an emerging theranostic modality for various cancers and diseases. It is a new approach in which active oxygen is produced to kill tumor cells when photosensitizer is activated by laser light. As a safe and efficient low-cost therapy with little side-effects, it has been approved for clinical application in antineoplastic and non-neoplastic diseases by countries like the USA, France, Holland and Canada, etc.
The Photodynamic Therapy Research Team led by Wang Xiaobing, associate professor of the School of Life Science of Shaanxi Normal University, published their research Analysis of the In Vivo and In Vitro Effects of Photodynamic Therapy on Breast Cancer by Using a Sensitizer, Sinoporphyrin Sodium in Theranostics (2015; 5(7): 772-786. doi: 10.7150/thno.10853), a top-ten journal in the medical field.
The article reported the spectrum characteristics and metabolic features of Chinese proprietary new photosensitizer Sinoporphyrin Sodium (DVDMS), and investigated the biological mechanism of proliferation inhibition and anti-metastasis of breast cancer with DVDMS-mediated PDT both in vivo and in vitro. The results suggest that DVDMS is more effective and has multiple advantages in inhibiting cancer growth and metastasis than Photofrin, a conventional clinically used photosensitizer approved by FDA in 1996. It has provided an important theoretical basis and innovative practice for clinical application of DVDMS.
This project was aided by SNNU's National Engineering Laboratory of Endangered Officinal Plant Resources Development in Northwest China, Ministry of Education Key Laboratory for Medicinal Plants Resources and Natural Medical Chemistry and SLS's Cellular Biochemistry Research Platform, and in collaboration with Chinese Academy of Medical Sciences and Qinglong High-Tech Co., which has significant theoretical and application values for developing new PDT medicine and improving PDT clinical efficacy.
Dr. Wang said, "DVDMS, as a Chinese proprietary new photosensitizer invented by the famous Professor Qicheng Fang, has a promising prospect. We hope to give more implication about DVDMS in the future PDT clinical usage through our investigation."
One of the SLS's research teams, PDT Antineoplastic Lab is led by Prof. Liu Quanhong and consists of young academic leader Wang Xiaobing, Xiangjiang Scholar Wang Pan, Dr. Zhang Kun and about 20 other doctoral and master's students.
Text by Sun Xiaodi, Feng Wei
Photo by Feng Wei